

MMHCC Newsletter March 2007

MouseLine

Mouse Models Offer Promise in the Science of Cancer Prevention

The new generation of genetically-engineered mouse models (GEMs) holds promise for helping cancer prevention researchers refine and speed up testing of potential preventive agents. These mice are programmed to develop specific types of cancer in ways that mimic human cancer. That may make it easier for scientists, using sophisticated imaging technologies, to gauge the effects of cancer preventive substances.



This summer, NCI will convene a "think tank" of 15-18 invited experts from the fields of early intervention, prevention, and prevention screening, as well as from the NCI Mouse Models of Human Cancers Consortium (MMHCC), to develop research plans that fully explore the promise of GEMs.

"The meeting will bring together a cadre of scientists from diverse fields," noted Dr. Cory Abate-Shen, professor with the Center for Advanced Biotechnology and Medicine, UMDNJ-Robert Wood Johnson Medical School. "This will facilitate a dialogue, which is critical. Working together, we can develop ideas for studies that will enable us to assess the value of these newer mouse models for cancer prevention."

In NCI's Division of Cancer Prevention (DCP), the Chemopreventive Agent Development Research Group, as well as many NCI funded investigators, have published more than a hundred studies using GEMs for the past decade. These studies in multiple organ systems have identified a variety of agents that have progressed to human clinical trials, including nonsteroidal anti-inflammatory drugs (NSAIDS), nitric-oxide-releasing NSAIDS, glucocorticoids, retinoid X receptor agonists, aromatase inhibitors, tazarotene, and ACAPHA (a mixture of Chinese herbs). However, more recently developed GEM models may be especially well suited to future prevention studies.

The upcoming think tank will address several key questions related to this, explained NCI's Dr. Cheryl Marks, who administers the MMHCC. "The intent of the meeting is to identify the principal challenges facing early intervention and prevention, define the future goals, identify limitations of mouse models and strategies to overcome those limitations, and discuss how to effectively use these newer mouse models for cancer prevention."

Until now, research with GEMs and other mouse models in the MMHCC has focused more on their applicability for safe and effective treatments for cancer rather than on prevention.







MouseLine cont.

Last year in *Toxicologic Pathology*, participants from a previous MMHCC workshop reported on precancer research. "The scientific community suddenly possesses a wealth of precancers available for study in a variety of organ systems," they wrote. "Since most of the GEMs have been constructed to test oncogenes or tumor suppressor genes known to be involved in human cancer, these precancers should become primary targets for understanding, treatment, and prevention and ideal representations of processes occurring in human precancers."

Dr. Abate-Shen noted that human clinical trials for cancer preventive agents can take many years before delivering definitive results, whether positive or negative, about the drug or nutritional supplement. "Our goal would be to test agents in these newer mouse models to understand their mechanism of action and to guide clinical studies," she said.

Source: NCI Cancer Bulletin, March 13, 2007

http://www.cancer.gov/ncicancerbulletin/cancerbulletin/page3

Repository News

The MMHCC Mouse Repository is an NCI-supported resource for the distribution of mouse cancer models and associated strains. The Repository makes strains available to all members of the scientific community. Up to 3 breeder pairs of each available strain may be ordered.

Newly accepted strains

The following strains have recently been accepted into the MMHCC Repository and are available for distribution (please click on the specific link, below, for additional information):

- 1. B6.129S6-*Tgfbr2* ^{tm1Hlm} (Tgfbr2 flox) http://mouse.ncifcrf.gov/available_details.asp?ID=01XN5
- 2. FVB-Tg(ACTB-SB10)1Dla (CAGGS-SB10) http://mouse.ncifcrf.gov/available_details.asp?ID=01XN7
- 3. FVB-TgTn(sb-T2/Onc)76Dla (76 T2/Onc) http://mouse.ncifcrf.gov/available_details.asp?ID=01XN8

More information can be found on the Mouse Repository's website: http://mouse.ncifcrf.gov







Meetings

April 9 - 14, 2007

Comprehensive Approaches to the in vivo Assessment of Cardiovascular Function in Mice

Bar Harbor, Maine

Meeting Information: http://www.jax.org/courses/events/coursedetails.do?id=434&detail=scope

April 10 - 13, 2007

Cambridge Healthtech Institute's – 8th Annual Microarrays in Medicine: Optimizing Diagnostics and Therapeutics

Boston, Massachusetts

Meeting Information: http://www.gotsummit.com

April 14 - 18, 2007 AACR 98th Annual Meeting

Los Angeles, California

Meeting Information: http://www.aacr.org/home/scientists/meetings--workshops/annual-meeting-2007.aspx

Please visit the **caMOD poster** at the AACR Poster Session for "Tumor Biology"

On Tuesday, April 17, 8:00 AM to 12:00 PM

Abstract No.: 3864

April 15 - 19, 2007

SBS 13th Annual Conference & Exhibition: Advancing the Science of Drug Discovery

Montreal, Canada

Meeting Information: http://www.sbsonline.org

April 27 - 28, 2007

34th Maine Biological and Medical Sciences Symposium

Salisbury Cove, Maine

Meeting Information: http://www.mdibl.org/courses/mbmss07.shtml

April 30 - May 2, 2007 5th Annual Bio-Tech Conference & Expo

Boston, Massachusetts

Meeting Information: http://www.bio-itworldexpo.com/







Notices and Funding Opportunities

Request for Information (RFI): Functional Validation of Environmentally-Responsive Genetic Variants

NOT-ES-07-006 National Institute of Environmental Health Sciences http://grants.nih.gov/grants/guide/notice-files/NOT-ES-07-006.html

Lung Cancer and Inflammation (R01)

RFA-CA-07-046
National Cancer Institute
http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-07-046.html

Diet Composition and Energy Balance (R01)

PA-07-218
Multiple Institutes
http://grants.nih.gov/grants/guide/pa-files/PA-07-218.html

Academic-Industrial Partnerships for Development and Validation of In Vivo Imaging Systems and Methods for Cancer Investigations (R01)

PAR-07-214
National Cancer Institute
http://grants.nih.gov/grants/guide/pa-files/PAR-07-214.html

The 2007 Annual Institutional Animal Care and Use Committee (IACUC) Conference: Excellence in Animal Care and Use-Path or Destination? March 26-27, 2007, San Diego, CA

NOT-OD-07-055

National Institutes of Health

http://grants.nih.gov/grants/guide/notice-files/NOT-OD-07-055.html

Technology Development for the Detection and Evaluation of Chemical and Biological Carcinogens (SBIR) [R43/R44]

PAS-07-240

National Cancer Institute

http://grants.nih.gov/grants/guide/pa-files/PAS-07-240.html

NOTICE: Administrative Supplements for Making Knockout Mice

NOT-HG-07-011

Multiple Institutes

http://grants.nih.gov/grants/guide/notice-files/NOT-HG-07-011.html









caBIG™ at the AACR Meeting

The Cancer Biomedical Informatics $Grid^{TM}$ (caBIGTM) is a virtual informatics infrastructure that connects data, research tools, scientists and institutions to leverage the combined strengths and expertise in an open environment with common standards. The mission of caBIGTM is to accelerate the discovery of new approaches for the detection, diagnosis, treatment, and prevention of cancer. Presentations will highlight some of the tools available to allow analysis of diverse data sources in order to enable integrative translational cancer research: integration of basic research data with tissue pathology and clinical data in a grid environment. Ultimately these tools will enable scientists, pathologists, and clinicians to improve the care and treatment of patients suffering from cancer. Applications discussed in this session will be demonstrated at the caBIGTM learning center.

cancer Biomedical Informatics Grid
NCI Sponsored Session
Monday, April 16th, 10:45 am-12:15 pm, Room 301 A-B

Presentations of caBIG tools developed to support translational research

10:45 am caBIG™ Overview Juli Klemm, National Cancer Institute, Rockville, MD
11:05 am The cancer Translational Research Informatics Platform (caTRIP) Patrick McConnell, Duke Comprehensive Cancer Center, Durham, NC
11:25 am caBench-to-Bedside (caB2B) Rakesh Nagarajan, Siteman Cancer Center, St. Louis, MO
11:15 am geWorkbench: an open-source, grid-enabled technology platform for integrated genomics Aris Floratos, Columbia University, NY
12:05pm Discussion

caBIG participants will be available to answer your questions about the caBIG program and open source tools.









caBIG Learning Center at the AACR Meeting Room 513

Live Demonstrations of caBIG Tools:

Monday, April 16th 1:00pm-5:00pm

1:00pm -3:00pm: caTRIP, caB2B, geWorkbench 3:00pm - 5:00pm: caArray and caMOD

Tuesday, April 17th 9:00am-12:00pm

9:00am – 10:00am: caArray and geWorkbench 10:00am – 12:00pm: Rembrandt, CGEMS, caMOD

caArray

A standards based database for microarray data management and annotation

caB2B - caBench-to-Bedside

Query of tissues and associated clinical and functional genomics data across multiple sites, and analyze these data using grid services

CGEMS - The Cancer Genetic Markers of Susceptibility

Access to SNP association findings, populations frequency, genotype, and phenotype data

caMOD - Cancer Models Database

Provides information about rodent and other animal models for human cancer to the research community

caTRIP - The cancer Translational Research Informatics Platform

Brings together disparate data sources such as tumor registry, tissue banks, pathology and SNP data to facilitate outcomes analysis

geWorkbench

Analysis and visualization tools for gene expression, sequences, pathways, and other biomedical data

Rembrandt - Repository of Molecular Brain Neoplasia Data

Ad hoc querying and reporting across multiple data domains, such as Gene Expression, Chromosomal aberrations and clinical data







Disclaimer

NCI does not endorse or recommend any commercial products, processes, or services described in this newsletter, or in any "off-site" external link web pages referenced in this newsletter or in the NCI emice website. The views and opinions of authors expressed in this newsletter do not necessarily state or reflect those of the United States Government and they may not be used for advertising or product endorsement purposes. Further, this newsletter is intended for informational purposes only. NCI does not warrant or assume any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed. NCI makes no warranties, either express or implied; including the warranties of merchantability or fitness for a particular purpose or that the use of this software or data will not infringe any third party patents, copyrights, trademark, or other rights.



